BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34551671)

  • 1. Downregulation of cell division cycle-associated protein 7 (CDCA7) suppresses cell proliferation, arrests cell cycle of ovarian cancer, and restrains angiogenesis by modulating enhancer of zeste homolog 2 (EZH2) expression.
    Cai C; Peng X; Zhang Y
    Bioengineered; 2021 Dec; 12(1):7007-7019. PubMed ID: 34551671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
    Chen XJ; An N
    J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2.
    Wang L; Ye TY; Wu H; Chen SY; Weng JR; Xi XW
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):201-208. PubMed ID: 31389610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
    Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
    Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UNC5B-AS1 promoted ovarian cancer progression by regulating the H3K27me on NDRG2 via EZH2.
    Wang H; Su H; Tan Y
    Cell Biol Int; 2020 Apr; 44(4):1028-1036. PubMed ID: 31903696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
    Yang X; Wang J; Li H; Sun Y; Tong X
    Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo.
    Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
    Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3.
    Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
    Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scutellarein induces apoptosis and inhibits proliferation, migration, and invasion in ovarian cancer via inhibition of EZH2/FOXO1 signaling.
    Lang X; Chen Z; Yang X; Yan Q; Xu M; Liu W; He Q; Zhang Y; Cheng W; Zhao W
    J Biochem Mol Toxicol; 2021 Oct; 35(10):e22870. PubMed ID: 34350670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
    Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4.
    Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
    Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
    Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
    Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
    Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-Associated Fibroblasts Promote Angiogenesis of Hepatocellular Carcinoma by
    Huang B; Huang M; Li Q
    Technol Cancer Res Treat; 2019; 18():1533033819879905. PubMed ID: 31757187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
    Xu L; Deng Q; Pan Y; Peng M; Wang X; Song L; Xiao M; Wang Z
    Int J Mol Med; 2014 Jan; 33(1):91-6. PubMed ID: 24212330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
    Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
    Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRABP2 accelerates epithelial mesenchymal transition in serous ovarian cancer cells by promoting TRIM16 methylation via upregulating EZH2 expression.
    Xie T; Tan M; Gao Y; Yang H
    Environ Toxicol; 2022 Aug; 37(8):1957-1967. PubMed ID: 35442568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.